Literature DB >> 8829787

Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.

P Weiden1, B Rapkin, A Zygmunt, T Mott, D Goldman, A Frances.   

Abstract

OBJECTIVE: This preliminary study assessed the effects on outpatient medication compliance of converting inpatients with schizophrenia from oral to depot neuroleptic medication.
METHODS: Subjects consisted of 93 neuroleptic-responsive inpatients with schizophrenia from three New York City hospitals who were part of a one-year prospective longitudinal study of medication compliance. Forty patients were converted to depot neuroleptic medication while hospitalized; the other 53 remained on oral medication. Symptoms, side effects, and medication compliance of the two groups were compared at one, six, and 12 months postdischarge.
RESULTS: Inpatients converted to depot medication had significantly better compliance at one month postdischarge. Differences in demographic characteristics, symptoms, hospital site, and baseline attitudes toward medication did not account for this finding. The initial positive effect on compliance waned, and no significant between-group differences in compliance were found at six and 12 months postdischarge.
CONCLUSIONS: Conversion to depot medication before hospital discharge may facilitate medication compliance during transition to outpatient treatment, but other interventions are needed to maintain compliance over time.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8829787     DOI: 10.1176/ps.46.10.1049

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  20 in total

Review 1.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

2.  Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors:  Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center.

Authors:  Dawn I Velligan; Elisa Medellin; Meredith Draper; Natalie Maples; Albana Dassori; Troy A Moore; Linda Lopez
Journal:  Community Ment Health J       Date:  2011-01-21

4.  Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Authors:  Natalie C Edwards; Marcia F T Rupnow; Chris L Pashos; Marc F Botteman; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Depot haloperidol decanoate for schizophrenia.

Authors:  S Quraishi; A David
Journal:  Cochrane Database Syst Rev       Date:  2000

6.  Assessment and treatment selection for "revolving door" inpatients with schizophrenia.

Authors:  P Weiden; W Glazer
Journal:  Psychiatr Q       Date:  1997

Review 7.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

8.  The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.

Authors:  Maju Mathew Koola; Heidi J Wehring; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2012

9.  What's in a name? Compliance, adherence and concordance in chronic psychiatric disorders.

Authors:  Subho Chakrabarti
Journal:  World J Psychiatry       Date:  2014-06-22

10.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.